Loading…
Barinthus Biotherapeutics plc is projected to rise to $0.587 by 2027, a +4% move from its current price of $0.5647. BRNS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/5/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 6 | $0.5423 | $0.5651 | $0.5889 | +0.07% |
| Aug 7 | $0.5335 | $0.5655 | $0.5994 | +0.15% |
| Aug 8 | $0.527 | $0.5659 | $0.6078 | +0.22% |
| Aug 9 | $0.5216 | $0.5663 | $0.615 | +0.29% |
| Aug 10 | $0.5169 | $0.5668 | $0.6214 | +0.36% |
| Aug 11 | $0.5127 | $0.5672 | $0.6274 | +0.44% |
| Aug 12 | $0.509 | $0.5676 | $0.6329 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.509 | $0.5676 | $0.6329 | +0.51% |
| Week 2 | $0.489 | $0.5705 | $0.6655 | +1.02% |
| Week 3 | $0.4747 | $0.5734 | $0.6925 | +1.53% |
| Week 4 | $0.4634 | $0.5763 | $0.7166 | +2.05% |
| Week 5 | $0.454 | $0.5792 | $0.739 | +2.57% |
| Week 6 | $0.4458 | $0.5822 | $0.7603 | +3.09% |
| Week 7 | $0.4386 | $0.5851 | $0.7807 | +3.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S.
National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Barinthus Biotherapeutics plc (BRNS) is a healthcare asset currently trading at $0.57. It has a market cap of $23.28M and is ranked 4607 by market capitalization.
A major floor 20.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.5% away) — a key level to hold.
The nearest ceiling, 27.3% above — a clean break opens room to run.
A major ceiling 37.8% above — clearing it would confirm fresh momentum.
Key BRNS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BRNS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.57 | Sell | $0.5734 | Sell |
| MA 10 | $0.5797 | Sell | $0.5809 | Sell |
| MA 20 | $0.60 | Sell | $0.5979 | Sell |
| MA 50 | $0.6472 | Sell | $0.6261 | Sell |
| MA 100 | $0.6343 | Sell | $0.6533 | Sell |
| MA 200 | $0.7123 | Sell | $0.7385 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.77 | Neutral |
| Stoch RSI (14) | 59.87 | Neutral |
| CCI (20) | -79.98 | Neutral |
| Williams %R (14) | -77.05 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -7.62 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 22.95 | Neutral |
| TRIX (15) | -0.50 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 37.14 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -4.00 | Sell |
| Hull MA (9) | 0.57 | Sell |
| ADX (14) | 13.93 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is bearish, with RSI(14) at 40. The SMA50 sits at $0.6646 and the SMA200 at $0.7458, indicating a short-term tilt below the longer-term trend. Immediate support is reported at $0.556 and resistance at $0.724, framing a near-term range roughly between $0.4228 and $0.7685 over the past 30 days.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.54 | $0.5647 | $0.8336 | 0% | Neutral | |
| $0.4468 | $0.587 | $0.827 | +4% | Neutral | |
| $0.442 | $0.6075 | $0.9026 | +8% | Neutral | |
| $0.4633 | $0.6614 | $1.02 | +17% | Neutral | |
| $0.4196 | $0.6196 | $0.9918 | +10% | Neutral | |
| $0.5459 | $0.8315 | $1.37 | +47% | Bullish | |
| $0.6275 | $0.9843 | $1.66 | +74% | Bullish | |
| $0.6046 | $0.9751 | $1.69 | +73% | Bullish | |
| $0.6529 | $1.08 | $1.91 | +92% | Bullish | |
| $0.5722 | $0.9725 | $1.75 | +72% | Bullish | |
| $0.8062 | $1.55 | $3.03 | +174% | Bullish | |
| $1.47 | $3.27 | $7.18 | +479% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.54 | $0.5647 | $0.723 | +0.00% |
| September 2026 | $0.4976 | $0.5967 | $0.7413 | +5.66% |
| October 2026 | $0.4978 | $0.6033 | $0.7618 | +1.12% |
| November 2026 | $0.5208 | $0.6367 | $0.8144 | +5.54% |
| December 2026 | $0.5228 | $0.6443 | $0.8336 | +1.19% |
Click any year to see its month-by-month BRNS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BRNS to range from $0.54 to $0.8336 through 2026. The $0.5647 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The BRNS price prediction for 2027 points to an average of $0.587 (low $0.4468, high $0.827) — a potential gain of +4% on today's $0.5647. A consolidation phase looks the most probable path here.
In 2028, BRNS is projected to trade between $0.442 and $0.9026, averaging $0.6075 — a potential gain of +8% from today's $0.5647. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
Barinthus Biotherapeutics plc's 2029 outlook centres on $0.6614, within a $0.4633 to $1.02 range. That is up +9% on the projected 2028 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, BRNS could reach as high as $0.9918, with a base case around $0.6196 and support toward $0.4196 — roughly +10% from $0.5647. Price action looks broadly range-bound.
Expect BRNS to range from $0.5459 to $1.37 through 2031. The $0.8315 average target implies a +47% move from current prices. That is up +34% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The BRNS price prediction for 2032 points to an average of $0.9843 (low $0.6275, high $1.66) — a potential gain of +74% on today's $0.5647. Momentum favours further upside here.
In 2033, BRNS is projected to trade between $0.6046 and $1.69, averaging $0.9751 — a potential gain of +73% from today's $0.5647. That is -1% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Barinthus Biotherapeutics plc's 2034 outlook centres on $1.08, within a $0.6529 to $1.91 range. That is up +11% on the projected 2033 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2035, BRNS could reach as high as $1.75, with a base case around $0.9725 and support toward $0.5722 — roughly +72% from $0.5647. Buyers look set to stay in control over this stretch.
Expect BRNS to range from $0.8062 to $3.03 through 2040. The $1.55 average target implies a +174% move from current prices. That is up +59% on the projected 2035 average. Momentum favours further upside here.
The BRNS price prediction for 2050 points to an average of $3.27 (low $1.47, high $7.18) — a potential gain of +479% on today's $0.5647. Buyers look set to stay in control over this stretch.
Investing $1,000 in BRNS today (≈ 1,770.85178 BRNS) could be worth
$5,788.46
+$4,788.46 (+479%) by 2050 · US Dollar
Based on the average projected BRNS price of $3.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BRNSwould be worth at today's price.
$1,000 invested in BRNS on Aug 5, 2025 (≈ 724.637684 BRNS) would be worth
$409.2
-$590.8 (-59.1%) today · 0.41× · US Dollar
Based on a BRNS entry price of $1.38 vs. today's $0.5647.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.574 | $983.8 | -1.6% |
| 1 month ago | $0.631 | $894.93 | -10.5% |
| 3 months ago | $0.67 | $842.84 | -15.7% |
| 6 months ago | $0.705 | $800.99 | -19.9% |
| 1 year ago | $1.38 | $409.2 | -59.1% |
| All time (5.0y) ago | $14.86 | $38 | -96.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BRNS forecast.
Our base-case forecast reaches $1.10 around 2040.
Implied market cap at $1.10: $44.93M
The multi-year forecast shows a shift from neutral to bullish sentiment beginning in 2031. The 2026-2030 window remains neutral, with average prices around $0.57 and $0.58 and modest upside to a max of $0.8515 in 2026. From 2031 onward, the forecast turns bullish, with 2031 avg $0.7827 and max $1.33, 2032 avg $0.9288 and max $1.62, 2033 avg $0.9193 and max $1.65, 2034 avg $1.02 and max $1.87, and 2035 avg $0.879 with max $1.64.
The long-range outlook projects continued upside, with 2040 avg $1.43 and max $2.91 and 2050 avg $2.86 and max $6.58, corresponding to ROI figures of 37.3, 62.9, 61.3, 79.4, 54.2, 150.6, and 402 respectively. These are estimates, not guarantees, and the forecast includes a wide potential range (min to max) across years, reflecting the asset’s volatility which is indicated at 90% annualized volatility.
Tap a question to reveal the answer.
2030 min $0.3787, avg $0.5761, max $0.9482; ROI 1.1; sentiment NEUTRAL.
Forecasts show neutral through 2030 and bullish from 2031 onward, with 2031 avg $0.7827 increasing to 2050 avg $2.86 and ROI rising to 402; sentiment shifts to BULLISH after 2030.
Yes, the 2032 forecast includes a max of $1.62 and an avg of $0.9288; min is $0.57, indicating possible movement above $1 within the year’s range.
The current price is $0.57.
2040 avg $1.43 with ROI 150.6, and 2050 avg $2.86 with ROI 402; the 2050 max is $6.58 and min $1.29, illustrating a broad upside potential alongside high volatility (annualized 90%).
Barinthus Biotherapeutics plc Community Discussion
0Share your Barinthus Biotherapeutics plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.